IR@PKUHSC  > 北京大学药学院
学科主题药学
Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer
Zeng, Fan; Ju, Rui-Jun; Liu, Lei; Xie, Hong-Jun; Mu, Li-Min; Zhao, Yao; Yan, Yan; Hu, Ying-Jie; Wu, Jia-Shuan; Lu, Wan-Liang
关键词functional liposome vincristine dasatinib vasculogenic mimicry channel triple-negative breast cancer
刊名ONCOTARGET
2015-11-03
6期:34页:36625-36642
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Cell Biology
资助者National Natural Science Foundation of China ; Beijing Natural Science Foundation ; National Natural Science Foundation of China ; Beijing Natural Science Foundation
研究领域[WOS]Oncology ; Cell Biology
关键词[WOS]SQUAMOUS-CELL CARCINOMAS ; ANTITUMOR-ACTIVITY ; CD133(+) CELLS ; APOPTOSIS ; SRC ; LEUKEMIA ; PATHWAYS ; SURVIVAL ; PEPTIDE ; KINASE
英文摘要

Standard chemotherapy cannot eradicate triple-negative breast cancer (TNBC) while the residual cancer cells readily form the vasculogenic mimicry (VM) channels, which lead to the relapse of cancer after treatment. In this study, the functional vincristine plus dasatinib liposomes, modified by a targeting molecule DSPE-PEG(2000)-c(RGDyK), were fabricated to address this issue. The investigations were performed on TNBC MDA-MB-231 cells and MDA-MB-231 xenografts in nude mice. The liposomes exhibited the superior performances in the following aspects: the enhancement of cellular uptake via targeted action; the induction of apoptosis via activation of caspase 8, 9, and 3, increased expression of Bax, decreased expression of Mcl-1, and generation of reactive oxygen species (ROS); and the deletion of VM channels via inhibitions on the VM channel indicators, which consisted of vascular endothelial-cadherin (VE-Cad), focal adhesion kinase (FAK), phosphatidylinositide 3-kinase (PI3K), and matrix metallopeptidases (MMP-2, and MMP-9). Furthermore, the liposomes displayed the prolonged circulation time in the blood, the increased accumulation in tumor tissue, and the improved therapeutic efficacy along with deletion of VM channels in the TNBC-bearing mice. In conclusion, the nanostructured functional drug-loaded liposomes may provide a promising strategy for the treatment of invasive TNBC along with deletion of VM channels.

语种英语
所属项目编号81373343 ; 7131009
资助者National Natural Science Foundation of China ; Beijing Natural Science Foundation ; National Natural Science Foundation of China ; Beijing Natural Science Foundation
WOS记录号WOS:000366111900119
Citation statistics
Cited Times:11[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59044
Collection北京大学药学院
作者单位Peking Univ, Beijing Key Lab Mol Pharmaceut & New Drug Syst, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Zeng, Fan,Ju, Rui-Jun,Liu, Lei,et al. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer[J]. ONCOTARGET,2015,6(34):36625-36642.
APA Zeng, Fan.,Ju, Rui-Jun.,Liu, Lei.,Xie, Hong-Jun.,Mu, Li-Min.,...&Lu, Wan-Liang.(2015).Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.ONCOTARGET,6(34),36625-36642.
MLA Zeng, Fan,et al."Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer".ONCOTARGET 6.34(2015):36625-36642.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Zeng, Fan]'s Articles
[Ju, Rui-Jun]'s Articles
[Liu, Lei]'s Articles
百度学术
百度学术Similar articles in
[Zeng, Fan]'s Articles
[Ju, Rui-Jun]'s Articles
[Liu, Lei]'s Articles
必应学术
必应学术Similar articles in
[Zeng, Fan]'s Articles
[Ju, Rui-Jun]'s Articles
[Liu, Lei]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.